| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Contrast Media |
1 From the Departments of Clinical Radiology (B.T., C.B., P.R., W.H.) and Internal Medicine (K.K., R.M.S.), Westfalian Wilhelms University of Münster, Albert-Schweitzer Str 33, Münster D-48129, Germany; and Schering, Berlin, Germany (V.G.). From the 1998 RSNA scientific assembly. Received November 10, 1999; revision requested January 5, 2000; revision received July 31; accepted August 30. Supported in part by Schering. Address correspondence to B.T. (e-mail: tombach@uni-muenster.de).
PURPOSE: To assess the renal tolerance of 1.0 mol/L gadobutrol as an electrically neutral contrast agent at magnetic resonance (MR) imaging in patients with impaired renal function.
MATERIALS AND METHODS: Twenty-one patients with impaired renal function were enrolled in this prospective randomized study and classified into two subgroups according to their creatinine clearance: group 1 (n = 12), less than 80 mL/min (<1.33 mL/sec) and greater than 30 mL/min (>0.50 mL/sec); group 2 (n = 9), less than 30 mL/min (<0.50 mL/sec) and not requiring dialysis. Gadobutrol (1.0 mol/L) was injected intravenously at randomly assigned doses of either 0.1 or 0.3 mmol per kilogram of body weight. Changes in vital signs, clinical chemistry, and urinalysis results, including creatinine clearance, were monitored before, at 6 hours, and then every 24 hours until 72 hours (group 1) or 120 hours (group 2) after intravenous injection of gadobutrol. Hematologic results were checked every other day.
RESULTS: No serious adverse event occurred, and no clinically relevant changes in vital signs, hematologic results, clinical chemistry, or urinalysis results were detected in the observation period. Markers for glomerular filtration (creatinine, cystatin C, ß2-microglobulin, creatinine clearance) and tubular function (N-acetyl-ß-D-glucosaminidase, 
1-microglobulin) were unaffected by gadobutrol in both groups.
CONCLUSION: Gadobutrol did not affect renal function and, therefore, proved to be a safe MR contrast agent in patients with impaired renal function. Even in patients with marginal excretory function (creatinine clearance, <30 mL/min [<0.50 mL/sec]), prehydration or treatment with diuretics or hemodialysis are not required after the administration of gadobutrol.
Index terms: Gadolinium • Kidney, failure, 81.699 • Kidney, MR, 81.12143 • Kidney neoplasms, MR, 81.32, 81.12143 • Magnetic resonance (MR), contrast media, 81.12143
This article has been cited by other articles:
|
|
 |
|
  G. Roditi MRI contrast agent safety in renal impairment Clin Risk, March 1, 2009; 15(2): 47 - 53. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ledneva, S. Karie, V. Launay-Vacher, N. Janus, and G. Deray Renal Safety of Gadolinium-based Contrast Media in Patients with Chronic Renal Insufficiency Radiology, March 1, 2009; 250(3): 618 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Habibi, M. S. Krishnam, D. G. Lohan, F. Barkhordarian, M. Jalili, R. S. Saleh, S. G. Ruehm, and J. P. Finn High-Spatial-Resolution Lower Extremity MR Angiography at 3.0 T: Contrast Agent Dose Comparison Study Radiology, August 1, 2008; 248(2): 680 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Fenchel, A Franow, P Martirosian, M Engels, U Kramer, N I Stauder, U Helber, H Vogler, C D Claussen, and S Miller 1 M Gd-chelate (gadobutrol) for multislice first-pass magnetic resonance myocardial perfusion imaging Br. J. Radiol., November 1, 2007; 80(959): 884 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Boss, P. Martirosian, M. Gehrmann, F. Artunc, T. Risler, N. Oesingmann, C. D. Claussen, F. Schick, K. Kuper, and H.-P. Schlemmer Quantitative Assessment of Glomerular Filtration Rate with MR Gadolinium Slope Clearance Measurements: A Phase I Trial Radiology, March 1, 2007; 242(3): 783 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Andreisek, T. Pfammatter, K. Goepfert, D. Nanz, P. Hervo, R. Koppensteiner, and D. Weishaupt Peripheral Arteries in Diabetic Patients: Standard Bolus-Chase and Time-resolved MR Angiography Radiology, December 19, 2006; (2006) 2422051111. [Abstract] [Full Text]
|
|
|
|
|
|
M. Remy-Jardin, J. Bahepar, J.-J. Lafitte, P. Dequiedt, O. Ertzbischoff, J. Bruzzi, V. Delannoy-Deken, A. Duhamel, and J. Remy Multi-Detector Row CT Angiography of Pulmonary Circulation with Gadolinium-based Contrast Agents: Prospective Evaluation in 60 Patients Radiology, March 1, 2006; 238(3): 1022 - 1035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Prokop, G. Schneider, A. Vanzulli, M. Goyen, S. G. Ruehm, P. Douek, M. Dapra, G. Pirovano, M. A. Kirchin, and A. Spinazzi Contrast-enhanced MR Angiography of the Renal Arteries: Blinded Multicenter Crossover Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine Radiology, February 1, 2005; 234(2): 399 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Erley, B. D. Bader, E. D. Berger, N. Tuncel, S. Winkler, G. Tepe, T. Risler, and S. Duda Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotaemic patients Nephrol. Dial. Transplant., October 1, 2004; 19(10): 2526 - 2531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Doorenbos, A. Ozyilmaz, and M. van Wijnen Severe Pseudohypocalcemia after Gadolinium-Enhanced Magnetic Resonance Angiography N. Engl. J. Med., August 21, 2003; 349(8): 817 - 818. [Full Text] [PDF]
|
|
|
|
|
|
B. Tombach, T. Benner, P. Reimer, G. Schuierer, E.-M. Fallenberg, V. Geens, T. Wels, and A. G. Sorensen Do Highly Concentrated Gadolinium Chelates Improve MR Brain Perfusion Imaging? Intraindividually Controlled Randomized Crossover Concentration Comparison Study of 0.5 versus 1.0 mol/L Gadobutrol Radiology, March 1, 2003; 226(3): 880 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Sonnad Describing Data: Statistical and Graphical Methods Radiology, December 1, 2002; 225(3): 622 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Spinosa, J. A. Kaufmann, and G. D. Hartwell Gadolinium Chelates in Angiography and Interventional Radiology: A Useful Alternative to Iodinated Contrast Media for Angiography Radiology, May 1, 2002; 223(2): 319 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Tombach, C. Bremer, P. Reimer, F. Matzkies, R. M. Schaefer, W. Ebert, V. Geens, J. Eisele, and W. Heindel Using Highly Concentrated Gadobutrol as an MR Contrast Agent in Patients Also Requiring Hemodialysis: Safety and Dialysability Am. J. Roentgenol., January 1, 2002; 178(1): 105 - 109. [Abstract] [Full Text] [PDF]
|
|
